As the HR pathway is only active after DNA double-strand breaks in proliferating cells, we evaluated RAD51 IHC after the exclusion of low-γH2AX (DNA damage marker)- or low-geminin (G2/S phase marker)-expressing tumor samples. The gene discussed is RAD51; the disease is neoplasm.